Slide1

AKESOgen’s CSO wins prestigious Innovation Award at the Annual Partnership Gwinnett Summit

 

IMG_4764

IMG_4770

Atlanta, GA – 11th December 2015 – Dr. Bouzyk, a nominated finalist, was today announced as the Winner of the “Innovation” category for the Annual Partnership Gwinnett Awards.

The winners were announced at the Awards Luncheon during the Annual Partnership Gwinnett Summit at Georgia Gwinnett College. Preceding the luncheon a half-day program focused on Gwinnett’s 2015 economic successes, as well as highlighting progress in the areas of education, redevelopment, and entrepreneurship.

“ I am delighted to have received this prestigious Innovation Award on behalf of my colleagues at AKESOgen who are the real Innovators in the expanding field of genomics and Precision Medicine. We are also grateful to the Gwinnett Chamber of Economic Development for the outstanding infrastructure and support they provide to enable life science companies such as AKESOgen to flourish.” commented Dr. Bouzyk.

 About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com

Media Contact:

Crystal Yang, Client Relations Specialist, Scientific Affairs, AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or cyang@akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
ICB-mark presenting

AKESOgen’s CSO delivers plenary lecture at the third annual International Conference on Biomarkers Discovery and Clinical Application, Shanghai, China

 

Shanghai, China– 17th-18th October, 2015- Personalized medicine and genomics company, AKESOgen, attended and spoke at the third annual International Conference on Biomarkers Discovery and Clinical Application (ICB) in Shanghai, China  as an industry expert on genomic profiling in multiple cancers.  The ICB brought together international pharmaceutical, biotech and diagnostics companies, leading universities and institutions, healthcare, government, and national labs, CROs and tool providers.  The third annual ICB focussed on the following:

  • Trends in Biomarker Research
  • Biomarkers and translational medicine
  • Biomarkers in drug development
  • Innovation in biomarker discovery

“International conferences such as the ICB marks the impact that genomic information, shared internationally, can provide to improving precision medicine” said Mark Bouzyk, CSO of AKESOgen.

ICB logo-Shanghai           AKESOgen-Logo333

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
ASHG Logo-2015

AKESOgen at ASHG

AKESOgen scientists attended ASHG in Baltimore, MD, October 7-
9, 2015. Please email info@akesogen.com or call 770 542 0890 to discuss your genomics needs.

HighResLog-oldMark_at_ASHG15ASHG Logo-2015

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
biodiscovery logo

BioDiscovery and AKESOgen announce their co-marketing partnership

Hawthorne, CA and Atlanta, GA, September 23, 2015 – BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions for life sciences research and clinical applications, and AKESOgen, a premier genomics services provider for clinical trials, clinical testing, and research, are excited to announce their new co-marketing partnership. Combining the expertise of the two companies will provide a complete end-to-end solution for clients seeking cytogenomic array and next-generation sequencing (NGS) services.

 

“Our partnership with AKESOgen provides customers with any throughput level, a proven, high quality, comprehensive system that enables them to be up and running in a short amount of time. Samples processed at AKESOgen labs and analyzed in BioDiscovery’s software are delivered to the user ready for review and reporting in one well-integrated workflow,” said Soheil Shams, Ph.D., CEO, BioDiscovery, Inc.

Data obtained from AKESOgen’s state-of-the-art laboratory is easily loaded into BioDiscovery’s powerful platform-independent, and user-friendly software solutions for analysis and reporting allowing users to easily process their samples and convert raw data into meaningful results.  This collaboration provides clients with a seamless sample processing and analysis pipeline for a start to finish high quality service.

 

“We are excited to be working with a company such as BioDiscovery, who provide an outstanding portfolio of genomic analysis tools.  We believe that our quality data generation capabilities perfectly complement BioDiscovery’s informatics solutions.  Together, our joint resources will provide a complete end to end, white glove service for the genomics investigator or clinician in precision medicine” said Mark Bouzyk, Ph.D., AKESOgen’s Chief Scientific Officer.

 

To launch off this relationship at the 2015 ASHG Annual Meeting, Mark Bouzyk, will be at the BioDiscovery Booth #603-605 on Wednesday, Oct. 7 from 4:30 pm – 5:30 pm and Thursday, Oct. 8 from 9:00 am – 10:00 am for anyone interested in a one-on-one demo.  No reservation needed.

 

AKESOgen offers full lab services starting with nucleic acid extraction to high-throughput microarray and next-generation sequencing for genotyping, copy number variation, and gene expression.  AKESOgen also provides bio-banking services in their state of the art, 14,000 square foot facility.  As a CLIA certified laboratory and state-licensed in GA, FL, and CA, AKESOgen provides highest quality clinical services that are rapid and cost-effective.

 

BioDiscovery’s platform-independent software packages provide a complete spectrum of data analysis solutions for gene expression (RNASeq, mRNA, miRNA) and copy number and sequence variation from microarray and NGS (WES, WGS, targeted panels) technologies. Nexus Copy Number is a user-friendly and robust software with specialized cancer specific tools and algorithms and the capability to handle large volumes of data.  With its ability to integrate data from different modalities (gene expression, copy number, sequence variation), it offers a complete picture of the genomic landscape.  BioDiscovery’s NxClinical increases accuracy and efficiency in molecular genetics and cytogenomics labs’ workflows.  It is a multi-user system with a central database, automated and standardized processes, and integrated reference databases to provide robust and rapid interpretation and reporting of genomic variations.

 

About BioDiscovery, Inc.

BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications.  The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use.  From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images.  Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care.  For more information, visit http://www.biodiscovery.com.

About AKESOgen

AKESOgen, is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research.  Based in Atlanta, GA, the company’s main focus is oncology and personalized medicine.  AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards.  For more information, visit www.akesogen.com

The BioDiscovery software tools mentioned are designed to assist clinicians and are not intended as primary diagnostic tools. It is each lab’s responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.


BioDiscovery Contact:

Shalini Verma

MarCom Manager

+1 310-414-8100

MarCom@biodiscovery.com

 

Akesogen Contact:

Crystal Yang,

Client Relations Specialist

+1 770-542-0890

cyang@akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen makes Annual List of America’s Fastest-Growing Private Companies—the Inc.500

HighResLog-old

AKESOgen makes Annual List of America’s Fastest-Growing Private Companies—the Inc.500

AKESOgen Ranks as the No. 44 Healthcare Company and 363rd Overall on the 2015 Inc.500 with Three-Year Sales Growth of 1,300%

NEW YORK and ATLANTA, August 12, 2015Inc. magazine today ranked the genomics services provider, AKESOgen, 44th as a Healthcare company and 363rd overall on its 34th annual Inc.500|5000, an exclusive ranking of the nation’s fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy—America’s independent entrepreneurs. Companies such as Intuit, Zappos, Under Armour, Microsoft, GoPro, Timberland, Clif Bar, Patagonia, Oracle, and many other well-known names gained early exposure as members of the Inc.500|5000.

“We are delighted to be recognized as an Inc.500 honoree with such well known organizations in 2015 as Fitbit, Smashburger, Bowlmor AMF, Planet Fitness, Giftcards.com, Radio Flyer, Box, and Mindbody.” commented AKESOgen CEO Robert Boisjoli.

“Genetics and Precision Medicine are becoming more and more pervasive in our society. As a result, there is an unprecedented need for genomics capabilities in clinical trials and diagnostics, in addition to research. AKESOgen is at the forefront of providing these molecular technologies for 21st century personalized medicine.” says Mark Bouzyk, AKESOgen’s CSO.

This year’s crop of Inc.500 companies is the most competitive in the list’s history. “For 34 years, Inc. has welcomed the fastest-growing companies in America into a very exclusive club. To make it among the top 500 companies on the list, honorees had to have grown at least tenfold over the past three years. That’s a result most businesses could only dream of…” says Inc. President and Editor-In-Chief Eric Schurenberg.

Complete results of the Inc.500|5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc500.

About Inc. Magazine

Founded in 1979 and acquired in 2005 by Mansueto VenturesInc. Magazine is the only major brand dedicated exclusively to owners and managers of growing private companies.  Total monthly audience reach for the brand has reached over 6,000,000 in 2015.  For more information, visit www.inc.com

About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com

Media Contact:

Crystal Yang, Client Relations Specialist, Scientific Affairs, AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or cyang@akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
Unknown

NSH Molecular Course Outline October 26-28 2015

 

AKESOgen-Logo333targos logo

AKESOgen, a leader in personalized medicine and genomics, has partnered with Targos and the National Society of Histotechnology to create and assemble an inaugural course on In-situ Hybridization, Microarray & Next-Generation Sequencing in Clinical Diagnostics.  The course will be held at the Emory conference center on Oct 26th-28th, 2015.  Please click the link below to view the agenda.  Additionally, the course will provide CEU credits.

NSH Molecular Course Outline October 26-28 2015

 

Emory Conference Center Hotel

Please click the link below to register for the course.

Registration of NSH Molecular Course Outline October 26-28 2015

About AKESOgen, Inc. 

AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

About the National Society of Histotechnologists

NSH is the premier source of learning, knowledge and future-oriented research for histology professionals. Attendance provides resources, education, ideas and advocacy to enhance the performance in the laboratory and ultimately the best patient care.

http://www.histoconvention.org/

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
florida CLIA logo

AKESOgen receives State of Florida Licensure to offer Clinical Testing

Atlanta, GA –June 30th, 2015– Personalized medicine and genomics company AKESOgen today announced that its CLIA-compliant laboratory has received the Florida Clinical Laboratory License, which will allow the company to perform its oncology testing services on patient samples from the state of Florida.

The Georgia based company said in a statement that it believes its cytogenomics tests for a wide spectrum of solid and liquid tumors will be of particular benefit to the state –as the test is offered as a complement to NGS clinical oncology testing.

“This endorsement by the State of Florida for AKESOgen provide our comprehensive oncology tests and services gives AKESOgen access to the single largest US oncology diagnostics market, and will help accelerate our commercial growth in this sector.” said Mark Bouzyk, CSO of AKESOgen.

About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

CSO of AKESOgen to speak at and attend the Third International Conference on Biomarkers Discovery and Clinical Application.

AKESOgen scientists to attend the third ICB conference in Shanghai, China from October 17-18, 2015.  AKESOgen’s CSO, Mark Bouzyk, has been invited to speak as a leading expert on genomic profiling in multiple cancers, specifically towards Precision Medicine.

ICB logo-Shanghai           AKESOgen-Logo333

Please email info@akesogen.com or call 770 542 0890 if you want to schedule an appointment with a delegate or to discuss your genomics needs.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
bio1

AKESOgen to host and sponsor Industry tour on behalf of Georgia Bio

Please join Georgia Bio’s Emerging Leaders Network on their Industry Tour for an inside look of AKESOgen, a premier provider of genetic analysis.

This industry tour will provide participants an inside look of AKESOgen, a leader in personalized medicine and genomics.  Equipped with industry experts, AKESOgen provides high quality genomic analysis services, performing over 21,000 whole genome genotyping monthly. It is the only facility in the United States that has developed and performs clinical commercial copy number alteration (CNA) microarray analysis for formalin-fixed, paraffin-embedded (FFPE) tissue samples on Illumina platforms. AKESOgen provides contract research, clinical diagnostic and clinical trial services to pharmaceutical, biotech, academic, and government research institutions.  The company supported over 100 academic investigators in 2014.

All participants should be dressed smart casual with closed toe shoes.

To register for this event and further details please go to: http://www.gabio.org/events/event_details.asp?id=600212

When:
Wednesday, September 09, 2015
10:30 am – 12:30 pm

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
20150623_132544

AKESOgen at Festival of Genomics

AKESOgen scientists attended and spoke at Front Line Genomics’ first inaugural Festival of Genomics Convention in Boston, MA, June 22-24, 2015. Please email info@akesogen.com or call 770 542 0890 if you want to schedule an appointment with a delegate or to discuss your genomics needs.

AKESOgen-Logo333frontline genomics

 

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail